menu
    • menu
    [{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Published in a Peer Reviewd Journal Provides Human Data Confirming Potential of Inflammasome's Proprietary Compounds for AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Kamuvudines","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Inflammasome Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inflammasome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inflammasome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Inflammasome to Develop Dual Sustained-Release HIV Prevention Implant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Funding","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Inflammasome Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Sustained-release Implant","sponsorNew":"Inflammasome Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Inflammasome Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Shows Multiple Inflammasomes Combine to Cause Lupus, Macular Degeneration and Other Neuroinflammatory Diseases Such as Alzheimer\u2019s Disease and Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Kamuvudine Derivative","moa":"NLRP3","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Inflammasome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Inflammasome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Inflammasome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inflammasome Therapeutics Announces First Patient Dosed in Phase I Diabetic Macular Edema Study of the Dual Inflammasome Inhibitor K8","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Kamuvudine-8","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Inflammasome Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inflammasome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflammasome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inflammasome Completes Enrollment For Dual Inhibitor Study in Ophthalmic Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Kamuvudine-9","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Inflammasome Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inflammasome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Inflammasome Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Inflammasome Therapeutics

    Menu

    Inflammasome Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Inflammasome Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Inflammasome Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Kamuvudine-9

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inflammasome Completes Enrollment For Dual Inhibitor Study in Ophthalmic Diseases

                            Details : Company has completed enrollment of Phase I of its brain and retina penetrant drug K9 (kamuvudine-9), which has application in multiple neuroinflammatory, degenerative diseases & autoimmune diseases.

                            Brand Name : K9

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 10, 2024

                            Lead Product(s) : Kamuvudine-9

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Inflammasome Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Inflammasome Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Kamuvudine-8

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inflammasome Therapeutics Announces First Patient Dosed in Phase I Diabetic Macular Edema Study of the Dual In...

                            Details : SOM-401 (K8) is a derivative of a nucleoside reverse transcriptase inhibitor. It is being evaluated in phase 1 clinical trials for the treatment of Diabetic Macular Edema.

                            Brand Name : SOM-401

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 18, 2024

                            Lead Product(s) : Kamuvudine-8

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Inflammasome Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Inflammasome Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Kamuvudine Derivative

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Study Shows Multiple Inflammasomes Combine to Cause Lupus, Macular Degeneration and Other Neuroinflammator...

                            Details : Kamuvudines, effectively inhibit activation of both NLRP3 and NLRC4 have been found to be extremely effective in pre-clinical models of macular degeneration, Parkinson’s disease and multiple sclerosis.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 06, 2021

                            Lead Product(s) : Kamuvudine Derivative

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Inflammasome Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Inflammasome Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Islatravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $1.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Inflammasome to Develop Dual Sustained-Release HIV Prevention Implant

                            Details : The grant will be used to develop a 12-month bioerodible implant for women against HIV infection coupled with birth control. The implant is expected to deliver a constant level of islatravir for HIV prevention and concurrently a consistent low plasma lev...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 09, 2021

                            Lead Product(s) : Islatravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $1.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Inflammasome Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Inflammasome Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Kamuvudines

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Study Published in a Peer Reviewd Journal Provides Human Data Confirming Potential of Inflammasome's Proprieta...

                            Details : The PNAS paper found that low toxicity derivatives of NRTIs (Kamuvudines) also block inflammasome activation and are at least as effective as NRTIs in dry AMD.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 01, 2021

                            Lead Product(s) : Kamuvudines

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth